In what would be the largest acquisition ever for Johnson & Johnson (NYSE:JNJ) if they decide to go through with it and can pull it off, they are reportedly mulling over a $20 billion bid for Switzerland's Synthes, one of the leading competitors in the orthopedic devices market.
Included in products manufactured and marketed by Synthes are instruments, implants and biomaterials for the surgical fixation and regeneration of human skeleton and its soft tissues, and for operative treatment of bone fractures.
A source cited by the Wall Street Journal says the negotiations are ongoing and "fragile," with both companies looking at the resulting combined control of over 50 percent of the trauma market, which would inevitably invite intense regulatory scrutiny.
The trauma market is valued overall at about $5.5 billion.
Johnson & Johnson was trading at $60.50, falling $0.06, or 0.10 percent, as of 12:31 PM EDT.
Monday, April 18, 2011
J&J (JNJ) Looking at $20 Billion Bid for Synthes
Labels:
Johnson and Johnson,
Synthes
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment